Ticagrelor Patent Expiration

Ticagrelor is used for reducing the rate of cardiovascular events, including myocardial infarction and stroke, in patients with coronary artery disease or who had acute coronary syndrome. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Brilinta on Jul 20, 2011. 13 different companies have introduced drugs containing Ticagrelor.


Ticagrelor Patents

Given below is the list of patents protecting Ticagrelor, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Brilinta US10300065

(Pediatric)

Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction Jul 27, 2036 Astrazeneca
Brilinta US10300065 Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction Jan 27, 2036 Astrazeneca
Brilinta US8425934

(Pediatric)

Pharmaceutical compositions Oct 17, 2030 Astrazeneca
Brilinta US8425934 Pharmaceutical compositions Apr 17, 2030 Astrazeneca
Brilinta USRE46276

(Pediatric)

Triazolo(4,5-D)pyrimidine compounds Apr 30, 2025

(Expired)

Astrazeneca
Brilinta USRE46276 Triazolo(4,5-D)pyrimidine compounds Oct 30, 2024

(Expired)

Astrazeneca
Brilinta US7265124 Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound Jul 09, 2021

(Expired)

Astrazeneca
Brilinta US7265124 Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound Jul 09, 2021

(Expired)

Astrazeneca
Brilinta US6525060 Triazolo(4,5-d)pyrimidine compounds Dec 02, 2019

(Expired)

Astrazeneca
Brilinta US6525060 Triazolo(4,5-d)pyrimidine compounds Dec 02, 2019

(Expired)

Astrazeneca
Brilinta US7250419 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition Dec 02, 2019

(Expired)

Astrazeneca
Brilinta US7250419 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition Dec 02, 2019

(Expired)

Astrazeneca
Brilinta US6251910 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists Jul 15, 2018

(Expired)

Astrazeneca
Brilinta US6251910 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists Jul 15, 2018

(Expired)

Astrazeneca



Ticagrelor's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ticagrelor Generic API Manufacturers

Several generic applications have been filed for Ticagrelor. The first generic version for Ticagrelor was by Watson Laboratories Inc and was approved on Sep 4, 2018. And the latest generic version is by Invagen Pharmaceuticals Inc and was approved on May 5, 2025.

Given below is the list of companies who have filed for Ticagrelor generic, along with the locations of their manufacturing plants worldwide.


1. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB May 1, 2025


Manufacturing Plant Locations
New

Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.

Country City Firm Name
India
Vadodara Alembic Pharmaceuticals Ltd
Vadodara Alembic Pharmaceuticals Limited
Panchmahal Alembic Pharmaceuticals Limited (Units I and II)
Panchmahal Alembic Pharmaceuticals Limited
Panelav Alembic Pharmaceuticals Limited
Vadodara Alembic Pharmaceuticals Ltd (API Division, Karakhadi)
Vadodara Alembic Pharmaceuticals, Ltd





2. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Apr 21, 2023





3. AMNEAL

Amneal Eu Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Discontinued ORAL N/A Jan 23, 2019


Manufacturing Plant Locations
New

Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.

Country City Firm Name
United States
Brookhaven Amneal Pharmaceuticals of New York, LLC
Bridgewater Amneal Complex Products Research LLC
Piscataway Amneal Pharmaceuticals, LLC
Hauppauge Amneal Pharmaceuticals of New York, LLC
Branchburg Amneal Pharmaceuticals, LLC
East Hanover Amneal Pharmaceuticals LLC
Glasgow Amneal Pharmaceuticals LLC
Paterson Amneal Pharmaceuticals, Llc
India
Hyderabad Amneal Oncology Private Limited
Matoda Amneal Pharmaceuticals Private Ltd.
Tal Bavla, Ahmedabad Amneal Pharmaceuticals Pvt. Ltd.
Ahmedabad Amneal Pharmaceuticals Private Ltd.





4. APOTEX

Apotex Inc has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB May 1, 2025


Manufacturing Plant Locations
New

Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.

Country City Firm Name
United States
Weston Apotex Corp.
Canada
North York Apotex Inc.
Brantford Apotex Pharmachem Inc.
Winnipeg Apotex Fermentation Inc.
Toronto Apotex Inc.
Etobicoke Apotex, Inc.
Richmond Hill Apotex Inc.
India
Bangalore Apotex Pharmachem India Pvt Ltd.
Bangalore Apotex Research Private Limited - Bioequivalence Centre
Bengaluru Apotex Research Private Limited





5. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Oct 29, 2024





6. HISUN PHARM HANGZHOU

Hisun Pharmaceutical Hangzhou Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Hisun Pharm Hangzhou.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Jan 23, 2019





7. INVAGEN PHARMS

Invagen Pharmaceuticals Inc has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Invagen Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB May 5, 2025





8. MSN

Msn Laboratories Private Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Apr 7, 2020


Manufacturing Plant Locations
New

Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.

Country City Firm Name
India
Yadadri Bhuvanagiri District MSN Organics Private Limited
Rangareddy District MSN Laboratories Private Limited
Sangareddy MSN Laboratories Private Limited, R&D Center
Rangareddy District MSN Laboratories Private Limited (Formulations Division, Unit-II)
Isnapur MSN Laboratories Private Limited, Unit-II
Kamareddy MSN Life Sciences Private Limited
Sangareddy MSN Pharmachem Private Limited
Medak MSN LIFE SCIENCES PRIVATE LIMITED
Sangareddy MSN Laboratories Private Ltd.
Jinnaram, Sangareddy MSN Laboratories Private Limited - Formulations Division
United States
Piscataway MSN PHARMACEUTICALS INC





9. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Discontinued ORAL N/A Jul 9, 2021
60MG

tablet Discontinued ORAL N/A Jul 9, 2021


Manufacturing Plant Locations
New

Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.

Country City Firm Name
United States
Greensboro Mylan Pharmaceuticals Inc
San Carlos Mylan Pharmaceuticals Inc.
Saint Albans Mylan Technologies, Inc.
Morgantown MYLAN CONSUMER HEALTHCARE Inc.
Rockford Mylan Institutional, Inc.
Santa Barbara Mylandon LLC dba Debbie s Delights Santa Barbara Baking Co.
Morgantown Mylan Specialty, L.P.
India
Anekal Taluk, Bangalore Mylan Laboratories Limited
Sarigam Mylan Laboratories Limited
Pithampur, District Dhar Mylan Laboratories Limited
Aurangabad Mylan Laboratories Limited (FDF-2)
Bangalore Mylan Laboratories Limited
Hyderabad Mylan Laboratories Limited
Sinnar Mylan Laboratories Limited
Hosur Mylan Laboratories Limited
Canada
Etobicoke Mylan Pharmaceuticals ULC
Ireland
Inverin Mylan Teoranta





10. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Aug 16, 2024





11. SUNSHINE

Sunshine Lake Pharma Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Sunshine.

Strength Dosage Form Availability Application Pathway TE code Launch Date
90MG

tablet Prescription ORAL AB Apr 6, 2020


Manufacturing Plant Locations
New

Sunshine's manufacturing plants are situated in 6 countries - United States, Peru, India, Thailand, China, Mozambique. Given below are the details of these plant locations as well as the firm names of Sunshine as present at those locations.

Country City Firm Name
United States
Evergreen Sunshine Honey Bees LLC
Doral Sunshine Bottling Co, Inc.
Red Bay Sunshine Mills aka World Pet Care
Andrews Sunshine Dairy, LLC
Jacksonville Sunshine Peanut Company
Halifax Sunshine Mills, Inc.
Dublin Sunshine Mills, Inc
Portland Sunshine Dairy Foods Management LLC
Rochester Sunshine Fund Raising Co.
Bridgeville Sunshine Burger & Specialty Food Company, LLC
Augusta Sunshine Honey Inc.
Alhambra Sunshine Bakery
Glenwood Springs Sunshine & Moons, LLC
Tupelo Sunshine Mills, Inc.
Artesia Sunshine Evergreen Inc.
North Las Vegas Sunshine Fresh Nevada LLC
Indianapolis SUNSHINE INTERNATIONAL LLC
Maumee Sunshine Inc Of Nw Ohio
Columbus Sunshine Apiaries
Methuen Sunshine International Foods, Inc.
Peru
Tambogrande Sunshine Export S.A.C
India
Surat Sunshine Global Hospital
Thailand
Tha Mai Sunshine International
China
Dongguan Sunshine Lake Pharma Co., Ltd
Mozambique
Boane Sunshine Nut Limitada





12. WATSON LABS INC

Watson Laboratories Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
60MG

tablet Prescription ORAL AB Sep 4, 2018
90MG

tablet Prescription ORAL AB Sep 4, 2018





Ticagrelor News

Concerns arise over Ticagrelor as key studies for AstraZeneca's multi-billion dollar medication reveal inaccuracies.

20 Jun, 2025

BMJ identifies errors in major research related to AstraZeneca's popular heart medication, ticagrelor.

20 Jun, 2025

Key studies on the popular heart medication ticagrelor reveal inaccuracies - Medical Xpress

19 Jun, 2025

A Pharmacist's Overview of Major Patent Expirations: Looking Ahead to 2025 and Later

18 Apr, 2025

See More